Xcopri

DRUG2 trials

Sponsors

SK Life Science, Inc.

Conditions

Partial Epilepsy

Phase 1

Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

CompletedNCT04903314

SK Life Science, Inc.Partial Epilepsy

Start: 2021-05-27End: 2025-11-06Updated: 2026-03-31

Phase 3

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Active, not recruitingNCT05067634

SK Life Science, Inc.Partial Epilepsy

Start: 2022-01-10End: 2026-11-01Target: 140Updated: 2026-09-09